GD2-CAR T Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

The authors presented the clinical experience from the first four patients with H3K27M-mutant diffuse intrinsic pontine glioma/diffuse midline glioma treated with GD2-CAR T cells at dose level 1.